Eric Blasius Risser Sells 3,000 Shares of MacroGenics Inc (MGNX) Stock

MacroGenics Inc (NASDAQ:MGNX) SVP Eric Blasius Risser sold 3,000 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $18.38, for a total value of $55,140.00. Following the sale, the senior vice president now owns 33,806 shares of the company’s stock, valued at $621,354.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Eric Blasius Risser also recently made the following trade(s):

  • On Wednesday, May 22nd, Eric Blasius Risser sold 4,000 shares of MacroGenics stock. The stock was sold at an average price of $18.54, for a total value of $74,160.00.

MacroGenics stock traded down $0.31 during trading on Wednesday, reaching $18.43. 1,392,839 shares of the company’s stock were exchanged, compared to its average volume of 1,213,794. The company has a current ratio of 6.47, a quick ratio of 6.47 and a debt-to-equity ratio of 0.08. MacroGenics Inc has a 52-week low of $9.87 and a 52-week high of $32.32. The stock has a market cap of $914.62 million, a price-to-earnings ratio of -4.40 and a beta of 2.90.

MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.04). MacroGenics had a negative return on equity of 57.65% and a negative net margin of 256.47%. The business had revenue of $9.66 million for the quarter, compared to analysts’ expectations of $11.46 million. Analysts forecast that MacroGenics Inc will post -3.7 earnings per share for the current year.

MGNX has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $39.00 price objective (up from $34.00) on shares of MacroGenics in a report on Wednesday, February 6th. Nomura upped their price objective on MacroGenics from $41.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, February 7th. SunTrust Banks upped their price objective on MacroGenics to $40.00 and gave the stock a “buy” rating in a report on Thursday, February 7th. Citigroup upgraded MacroGenics from a “sell” rating to a “buy” rating and upped their price objective for the stock from $10.00 to $39.00 in a report on Thursday, February 7th. Finally, Cowen restated a “buy” rating on shares of MacroGenics in a report on Thursday, May 2nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $32.07.

A number of institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its position in MacroGenics by 3.7% during the 1st quarter. The Manufacturers Life Insurance Company now owns 25,971 shares of the biopharmaceutical company’s stock worth $467,000 after purchasing an additional 929 shares during the period. Legal & General Group Plc boosted its position in MacroGenics by 20.4% in the 4th quarter. Legal & General Group Plc now owns 7,432 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 1,261 shares during the last quarter. Northern Trust Corp boosted its position in MacroGenics by 0.3% in the 4th quarter. Northern Trust Corp now owns 524,500 shares of the biopharmaceutical company’s stock valued at $6,661,000 after buying an additional 1,644 shares during the last quarter. Stifel Financial Corp boosted its position in MacroGenics by 14.8% in the 4th quarter. Stifel Financial Corp now owns 18,034 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 2,327 shares during the last quarter. Finally, Marshall Wace North America L.P. purchased a new position in MacroGenics in the 1st quarter valued at about $59,000. 76.23% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/22/eric-blasius-risser-sells-3000-shares-of-macrogenics-inc-mgnx-stock.html.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.

Recommended Story: Stop Order

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.